NasdaqGS - Nasdaq Real Time Price USD

Walgreens Boots Alliance, Inc. (WBA)

Compare
9.48 +0.02 (+0.16%)
As of 1:52 PM EST. Market Open.
Loading Chart for WBA
DELL
  • Previous Close 9.46
  • Open 9.50
  • Bid 9.47 x 200
  • Ask 9.52 x 2100
  • Day's Range 9.42 - 9.69
  • 52 Week Range 8.22 - 27.05
  • Volume 6,079,352
  • Avg. Volume 20,862,393
  • Market Cap (intraday) 8.192B
  • Beta (5Y Monthly) 0.68
  • PE Ratio (TTM) --
  • EPS (TTM) -10.01
  • Earnings Date Jan 2, 2025 - Jan 6, 2025
  • Forward Dividend & Yield 1.00 (10.57%)
  • Ex-Dividend Date Nov 18, 2024
  • 1y Target Est 10.03

Walgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, Germany, the United Kingdom, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise. The International segment offers sale of prescription drugs and health and wellness, beauty, personal care, and other consumer products outside the United States; and operates pharmacy-led health and beauty retail businesses under the Boots brand stores in the United Kingdom, the Republic of Ireland, and Thailand, as well as the Benavides brand in Mexico and the Ahumada brand in Chile. The U.S. Healthcare segment provides VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments; Shields, a specialty pharmacy integrator and accelerator for hospitals; and CareCentrix, a participant in the post-acute and home care management sectors. Walgreens Boots Alliance, Inc. was founded in 1909 and is headquartered in Deerfield, Illinois.

www.walgreensbootsalliance.com

193,000

Full Time Employees

August 31

Fiscal Year Ends

Recent News: WBA

View More

Performance Overview: WBA

Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

WBA
61.90%
S&P 500
20.07%

1-Year Return

WBA
53.94%
S&P 500
31.41%

3-Year Return

WBA
77.12%
S&P 500
22.88%

5-Year Return

WBA
78.77%
S&P 500
86.74%

Compare To: WBA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: WBA

View More

Valuation Measures

Annual
As of 11/1/2024
  • Market Cap

    8.18B

  • Enterprise Value

    37.92B

  • Trailing P/E

    --

  • Forward P/E

    4.94

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.06

  • Price/Book (mrq)

    0.78

  • Enterprise Value/Revenue

    0.26

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.85%

  • Return on Assets (ttm)

    0.59%

  • Return on Equity (ttm)

    -75.97%

  • Revenue (ttm)

    147.66B

  • Net Income Avi to Common (ttm)

    -8.64B

  • Diluted EPS (ttm)

    -10.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.11B

  • Total Debt/Equity (mrq)

    277.90%

  • Levered Free Cash Flow (ttm)

    2.73B

Research Analysis: WBA

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 37.55B
Earnings -3B
Q4'23
Q1'24
Q2'24
Q3'24
0
10B
20B
30B
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

7.00 Low
10.03 Average
9.48 Current
14.00 High
 

Company Insights: WBA

Research Reports: WBA

View More
  • Walgreens Earnings: Caps Off 2024 on Promising Note; Store Closure Update Excites Investors

    Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,000 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.

    Rating
    Price Target
     
  • Walgreens Earnings: Caps Off 2024 on Promising Note; Store Closure Update Excites Investors

    Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,000 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.

    Rating
    Price Target
     
  • Mid Cap U.S. Pick List October 2024

    This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.

     
  • Mid Cap U.S. Pick List September 2024

    This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.

     

Top Analysts: WBA

View More

Overall Score

B of A Securities 58/100
Latest Rating
Underperform
 

Direction Score

B of A Securities 53/100
Latest Rating
Underperform
 

Price Score

Barclays 99/100
Latest Rating
Underweight
 

People Also Watch